Hospital Claim Denials Are Rising: Why CDI Is Your Best Defense Against the Wave

The fastest way to lose revenue you already earned is to let a payer take it back after the fact. That is what is happening across the country right now. Hospital claim denials are climbing, appeals are more expensive to work, and a growing share of the pressure lands on diagnoses that clinical documentation integrity teams know well: sepsis, respiratory failure, encephalopathy. The takeaway for hospital and health system leaders is simple. The most reliable way to reduce denials is to prevent them at the point of documentation, before the claim ever leaves the building, not only to fight them on appeal weeks later.

This post looks at why hospital claim denials keep rising, what a strong CDI program actually does about it, and how to build a defense that holds up under payer and regulatory scrutiny. We will keep the numbers grounded and the recommendations practical.

The Scale of the Problem, in Plain Numbers

The denial trend is not a hunch. It shows up consistently across independent data.

Average initial claim denial rates reached 11.81% in 2024, a 2.4% increase year over year, according to Kodiak Solutions benchmarking reported in 2025. What matters underneath that headline is the shift in composition: medical necessity denials rose while prior authorization denials fell. Payers are moving the fight downstream, contesting whether the care was justified and documented rather than only whether it was authorized.

Inpatient claims are feeling it most. The final denial rate for inpatient claims in 2023 was more than 50% higher than in 2021, an estimated $1.2 billion in revenue impact, per Kodiak Solutions data released in May 2024. A final denial is not a paperwork nuisance. It is money written off after the work is done and the cost is spent.

The cost of the fight itself has grown too. Hospitals and health systems spent an estimated $25.7 billion adjudicating claims with payers in 2023, up 23% from 2022, with the cost per denied claim rising to $57.23, according to Premier Inc. in February 2025. Here is the detail that should shape strategy: Premier reports that about 70% of denials are ultimately overturned. Most of these denials should never have been paid to contest in the first place. Every dollar spent re-litigating a correct claim is a dollar that produced no new care and no new revenue.

Providers see the trend directly. About 73% of providers said denials increased between 2022 and 2024, according to the Experian Health 2024 State of Claims report.

Put together, the picture is consistent. More denials, higher final denial rates on inpatient care, and a rising cost to argue about claims that were largely correct to begin with.

Why Hospital Claim Denials Keep Rising

Denials are going up for reasons that are structural, not seasonal. Three forces are driving most of it.

Payer behavior has shifted toward clinical scrutiny

The move from prior authorization denials to medical necessity denials, visible in the Kodiak data above, tells you where payers are focusing their energy. Instead of stopping care before it happens, they increasingly review the clinical story after the fact and ask whether the documentation supports the acuity billed. That puts the medical record, and the specificity of the language in it, at the center of the dispute.

Clinical validation has become its own battleground

A clinical validation denial is different from a coding denial. The coder can capture a diagnosis correctly, and the payer can still argue the underlying clinical criteria were not met or not documented well enough to support it. This is now a defining part of CDI work. According to the ACDIS 2025 CDI Week Industry Survey on denials, among CDI programs involved in denials, 87.73% handle clinical validation denials and 64.11% handle DRG validation denials, up from 54.66% in 2024. The same survey identifies the diagnoses that draw the most scrutiny: sepsis at 85%, respiratory failure at about 78%, and encephalopathy at about 57%. These are high volume, high weight conditions where the difference between a defensible claim and a downgrade often comes down to whether the record clearly connects clinical indicators, provider judgment, and treatment.

The ACDIS survey also notes that denials from Medicare Administrative Contractors rose to 20.55%, a reminder that the pressure is not limited to commercial payers.

Medicare Advantage has changed the math

Medicare Advantage is now a dominant force in inpatient revenue, and its authorization and denial activity is enormous. MA insurers made nearly 53 million prior authorization determinations in 2024 with a 7.7% denial rate, and 80.7% of appealed denials were overturned, according to KFF in 2026. An 80.7% overturn rate on appealed denials tells you the same thing the Premier overturn figure does: a large share of these denials do not survive contact with the actual clinical facts. They still cost the hospital time, staff, and delayed cash to reverse.

Regulation is tightening around this. CMS’s CY2024 Medicare Advantage rule requires MA plans to follow Traditional Medicare’s Two-Midnight Rule and bars internal criteria more restrictive than Traditional Medicare, as summarized by the American Hospital Association in 2023. This gives hospitals firmer ground to stand on, but only if the documentation and the utilization review record are strong enough to hold the line the rule protects.

The Front-Line Defense: CDI That Prevents Denials, Not Just Appeals Them

Most denial programs are built to react. A claim gets denied, someone works the appeal, and if the facts are on the hospital’s side, roughly seven in ten come back. That model treats a preventable problem as a permanent cost of doing business.

A strong CDI program changes where the work happens. Instead of proving after the fact that the care was justified, it makes the record so clear and clinically supported at the point of documentation that most disputes never start.

Accurate documentation and clinical validation up front

The single most effective denial prevention tactic is concurrent review: reading the chart while the patient is still in house, when the provider can still add the detail that supports the diagnosis. For the conditions payers target most, that means making sure the record shows the clinical indicators, the provider’s clinical judgment, and the treatment response that together validate a diagnosis like sepsis or respiratory failure. When those elements are present and connected, a clinical validation denial has far less to grab onto.

This is the core of clinical documentation integrity as a discipline. It is not about upcoding or chasing weight. It is about making the medical record an accurate, defensible account of how sick the patient actually was and what the care team actually did. Done well, that accuracy protects revenue and stands up to review at the same time.

Query quality and provider engagement

Denials often trace back to a vague or missing clarification. A well written, compliant query that resolves conflicting or nonspecific documentation before the claim goes out removes the ambiguity a payer would otherwise exploit. That takes CDI specialists who know the clinical criteria, know the compliant way to ask, and have working relationships with the physicians whose notes carry the record. Query quality is a leading indicator of denial risk. Programs that measure and improve it tend to see fewer downstream disputes.

CDI denials management that closes the loop

Prevention and appeals should not live in separate silos. The strongest programs run a feedback loop: the same clinical knowledge used to write the appeal on a DRG downgrade feeds back into concurrent review so the next chart is documented to avoid the same denial. This is what mature CDI denials management looks like. Every overturned denial becomes a lesson that reduces the next one, and the diagnoses that show up repeatedly in denials, sepsis and encephalopathy chief among them, get targeted education and tighter concurrent review.

The medical necessity connection

Because the growth is in medical necessity and inpatient status, denial defense is not only a documentation problem. It is also a status and level of care problem. That is where CDI and utilization review reinforce each other. A clean case management and utilization review process makes sure the admission status matches the clinical picture and the Two-Midnight expectation, so the medical necessity story and the documentation story tell the same thing. When CDI and UR are aligned, MA status denials have far less room to operate.

Coding integrity on the back end

Documentation and coding have to agree. Accurate, complete health information management and coding makes sure the codes reflect what the record supports, so a DRG assignment can be defended if a payer challenges it. A gap between what the physician documented and how the case was coded is exactly the seam a DRG validation denial pulls apart.

Staffing the Defense: Experienced People, Managed With QA

Denial prevention is labor that requires judgment. It depends on credentialed CDI specialists who understand clinical criteria, coding guidelines, and payer tactics, and who can hold a productive conversation with a physician. Many hospitals want that capability but cannot hire and retain enough of it, especially when a denial backlog spikes or a key team member leaves.

This is where Medovent Solutions works alongside hospital teams. Medovent provides experienced, credentialed, US-based CDI specialists and denials-support staff in a managed model with built-in quality assurance. All staffing is domestic. The people are experienced and credentialed, and the work is overseen with QA rather than handed off and forgotten. That combination matters for a risk-averse organization: you get added capacity to get ahead of the denial wave without giving up control of quality or compliance. The brand line captures the intent. Medovent is large enough to scale to your volume and small enough to care about how each chart and each appeal is handled.

Whether the immediate need is concurrent review capacity, a denials backlog that has to be worked down, or a sustained CDI denials management function, the model flexes to the situation while keeping the standard consistent.

What a Measured Response Looks Like

There is no need for alarm here, and there is no single silver bullet. The response that works is methodical.

• Review your denial data by type and by diagnosis. If clinical validation and DRG downgrades are growing, and if sepsis, respiratory failure, and encephalopathy show up repeatedly, your leverage is in documentation, not just appeals.
• Move effort upstream into concurrent review and query quality so fewer claims are worth denying.
• Align CDI, utilization review, and coding so the medical necessity, status, and documentation stories agree.
• Feed appeal outcomes back into education so the same denial does not recur.
• Add experienced capacity where your team is stretched, in a managed model that protects quality.

Do these consistently and the trend becomes manageable. The denials that remain are the ones genuinely worth contesting, and you stop paying to re-litigate claims that were correct all along.

Frequently Asked Questions

What is the difference between a clinical validation denial and a DRG denial?

A clinical validation denial argues that the clinical criteria for a documented diagnosis were not met or not clearly supported in the record, even if the diagnosis was coded correctly. A DRG denial, often a downgrade, challenges the diagnosis related group assigned to the claim, usually to move it to a lower weighted group. Both increasingly land on CDI teams. The ACDIS 2025 survey found that among CDI programs handling denials, 87.73% work clinical validation denials and 64.11% work DRG validation denials.

Why are Medicare Advantage denials such a large part of the problem?

Volume and behavior. KFF reports MA insurers made nearly 53 million prior authorization determinations in 2024 at a 7.7% denial rate, with 80.7% of appealed denials overturned. The high overturn rate means many denials do not hold up, but each one still costs the hospital time and delayed cash. CMS’s CY2024 rule requiring MA plans to follow the Two-Midnight Rule gives hospitals firmer footing, provided the documentation and utilization review record support the status billed.

Can CDI really reduce hospital claim denials, or is this an appeals issue?

Both, but prevention is where the leverage is. Premier reports about 70% of denials are ultimately overturned, which means a large share should never have been worth contesting. Strong concurrent documentation and clinical validation up front keep many of those disputes from starting, so your team spends less on appeals and writes off less revenue.

How does outside CDI staffing help without adding compliance risk?

The risk depends on the model. Medovent uses experienced, credentialed, US-based CDI specialists in a managed model with quality assurance, so you add capacity to work denials and strengthen concurrent review while keeping oversight of quality and compliance. That lets you respond to a backlog or a rising trend without lowering your standard.